SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

IOL Chemicals zooms on securing approval for Ibuprofen from CDE in China

29 Apr 2025 Evaluate

IOL Chemicals and Pharmaceuticals is currently trading at Rs. 68.29, up by 2.87 points or 4.39% from its previous closing of Rs. 65.42 on the BSE.

The scrip opened at Rs. 67.90 and has touched a high and low of Rs. 69.89 and Rs. 67.60 respectively. So far 86175 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 107.41 on 16-Sep-2024 and a 52 week low of Rs. 57.51 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 70.90 and Rs. 63.46 respectively. The current market cap of the company is Rs. 1998.34 crore.

The promoters holding in the company stood at 52.62%, while Institutions and Non-Institutions held 1.54% and 45.84% respectively.

IOL Chemicals and Pharmaceuticals has received approval for ‘Ibuprofen’ product from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), China. This approval authorizes the company to export Ibuprofen to the Chinese markets. Ibuprofen is a widely used non-steroidal anti-inflammatory drug (NSAID) effective in relieving pain, reducing inflammation, and lowering fever.

IOL Chemicals and Pharmaceuticals is India's one of the leading generic pharmaceutical companies, and is significant player in the Organic chemicals space.

IOL Chem & Pharma Share Price

91.16 5.66 (6.62%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×